InvestorsHub Logo
icon url

that_little_voice

06/30/21 9:50 AM

#172388 RE: C-20 #172383

Only the board can remove him. The board is owned and put in place by Nader and Kelly.

Yet another reason why Moneymonroe is way off thinking CYDY wants the SEC to come and investigate. The last thing they want is to have them look through all their emails etc.

Don't forget, the SEC fined CYDY for MATERIAL WEAKNESS and disclaimers for 9 years of their fillings. Yes, the settlement was a small amount BUT, it doesn't change the fact this is run like a back alley deli.

CytoDyn Inc. disclosed material weaknesses in each of its Forms 10-K over a period of nine years, from 2008 through 2016. CytoDyn included in its public filings the same, nearly boilerplate, disclosure of material weaknesses for nine consecutive years. CytoDyn remediated its material weaknesses and determined that ICFR was effective as of May 31, 2017. The Commission’s settled order includes violations of Exchange Act Section 13(b)(2)(B) and Rule 13a-15(a), thereunder, and payment of a $35,000 civil penalty.

https://www.sec.gov/litigation/admin/2019/34-84994.pdf
icon url

3X Charm

06/30/21 10:01 AM

#172389 RE: C-20 #172383

C 20- you will have a voice at the shareholders meeting…use it for good.

If LL is what we originally thought it to be, why does it consistently fail on trials? Either the trials are poorly designed by MANAGEMENT or it doesn’t work for COVID. That doesn’t make it a bad drug, it means that management is obtuse.

It wasn’t a poor decision to pursue COVID. It was a poor decision to back burner the closest money making venture, HIV, while pursuing COVID. No experienced pharma executives went after M2M …it was a total wasted effort. What was learned from that failure that was employed in S2C?…nothing because that failed also. We know it works for HIV, but others are catching up. LH raw numbers do not look good and NPs twisting of the metrics will be rejected by science. That is the major problem with NP he does not understand the scientific method and thinks anecdotal data and voodoo analysis will fool the scientific community. He will not accept the way things need to be done, which cause failure at every turn. Otherwise name a success.